Bortezomib is a potential drug for treating myeloma bone disease by downregulating TRAF6 to inhibit the function and maturation of osteoclasts in multiple myeloma, and MG132 can be used in combination with radiotherapy to treat pancreatic cancer by inducing autophagy and downregulating TRAF6 [155,156]. Here, TRAF6 is linked to pancreatic neoplasm.